ISC 2026: Investigational drug lowers repeat stroke risk with no bleeding tradeoff

Presented at the International Stroke Conference, primary results from the phase 3 OCEANIC‑STROKE trial showed that the oral factor XIa (FXIa) inhibitor asundexian reduced recurrent ischemic stroke by 26% in patients with acute non‑cardioembolic stroke or high‑risk transient ischemic attack (6.2% vs. 8.4% with placebo; hazard ratio, 0.74; 95% confidence interval, 0.65-0.84). The double‑blind trial randomized 12,327 patients within 72 hours of the index event to asundexian 50 mg daily or placebo on top of single or dual antiplatelet therapy. Importantly, stroke reduction wasn’t accompanied by an increase in major bleeding (as defined by International Society on Thrombosis and Haemostasis criteria), supporting the hypothesis that FXIa inhibition can dissociate antithrombotic efficacy from bleeding risk.

Clinical takeaway: While FXIa inhibition may emerge as a safer add‑on strategy for secondary stroke prevention, analysis of data is not yet complete.

Sources:

Sharma M, et al "Factor XIa inhibition with asundexian in acute non-cardioembolic stroke or high-risk transient ischemic attack: primary results of the OCEANIC-STROKE trial." Presented at International Stroke Conference 2026. https://eppro02.ativ.me/web/index.php?page=Session&project=ISC26&id=4446692

(2026, February 5). American Stroke Association. New medication may reduce chances of a second clot-caused stroke without bleeding risk [News release]. https://newsroom.heart.org/news/new-medication-may-reduce-chances-of-a-second-clot-caused-stroke-without-bleeding-risk